LGND · Ligand Pharmaceuticals Inc
$294.60
+5.78 (+2.00%)
At close · Aug 14
Market Cap
$5.87B
Shares
19.94M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$268.09M
+60.4%
FY2025
Net Income
$124.45M
+3186.6%
FY2025
Gross Margin
97.48%
+1.3pp
FY2018
Operating Margin
15.29%
+28.8pp
FY2025
Diluted EPS
$6.13
+2886.4%
FY2025
Operating Cash Flow
$49.36M
-49.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $290.54M | $268.09M | $167.13MG | $131.31M | $196.25M | $241.54M | $163.56M | $120.28M | $251.45M | $141.1M | $108.97M | $71.91M | $64.54M | $48.97M | $31.39M | $30.04M | $23.54M | $38.94M | |
| — | — | — | — | — | — | — | — | — | -$11.4M | -$12.18M | -$11.8M | -$4.86M | -$2.08M | -$2.92M | -$2.3M | $382K | — | |
| $12.37M | — | — | — | — | — | — | — | $6.34M | $5.37M | $5.57M | $5.81M | $9.14M | $5.73M | $3.6M | $4.91M | — | — | |
| $140.5M | — | — | — | — | — | — | — | $245.12M | $135.74M | $103.4M | $66.11M | $55.4M | $43.24M | $27.79M | $25.13M | — | — | |
| — | — | — | — | — | — | — | — | 97.48% | 96.2% | 94.89% | 91.93% | 85.84% | 88.3% | 88.53% | 83.66% | — | — | |
| $41.35M | $81.18M | $21.43M | $24.54M | $36.08M | $32.11M | $40.5M | $55.91M | $27.86M | $26.89M | $21.22M | $11.01M | $9.75M | $9.27M | $10.79M | $10.29M | $22.07M | $39.87M | |
| $103.43M | $92.45M | $78.65M | $52.79M | $70.06M | $46.79M | $60.01M | $41.88M | $37.73M | $28.65M | $27.65M | $25.4M | $22.57M | $17.98M | $15.78M | $14.58M | $12.83M | $15.21M | |
| — | — | — | — | — | $47.2M | $23.4M | $16.9M | $15.8M | $12.1M | $10.6M | $2.4M | $2.4M | $2.4M | $2.4M | $2.3M | $100K | — | |
| — | $33.78M | $35.24M | $36.52M | $51.53M | $51.07M | $25.69M | $18.36M | $12.78M | $10.96M | $11.29M | $2.63M | $2.66M | $2.66M | $2.73M | $2.79M | $2.21M | $4.63M | |
| $94.73M | $41M | -$22.61M | $11.94M | $3.04M | $103.85M | $37.5M | $807.08M | $163.73M | $68.08M | $43.89M | $27.33M | $19.63M | $14.94M | $193K | -$878K | -$29.3M | -$9.97M | |
| — | 15.29% | -13.53% | 9.09% | 1.55% | 42.99% | 22.93% | 670.99% | 65.11% | 48.25% | 40.27% | 38% | 30.41% | 30.51% | 0.61% | -2.92% | -124.5% | -25.6% | |
| — | $74.78M | $12.63M | $48.46M | $54.57M | $154.92M | $63.19M | $825.44M | $176.51M | $79.03M | $55.18M | $29.96M | $22.28M | $17.61M | $2.92M | $1.91M | -$27.09M | -$5.33M | |
| $6.19M | $4.72M | $3.04M | $656K | $1.8M | $19.62M | $27.42M | $35.75M | $48.28M | $13.46M | $12.84M | — | $4.86M | $2.08M | $2.92M | $2.51M | $58K | $270K | |
| $24.22M | $13.66M | $8.06M | $7.71M | $2.05M | $886K | $8.08M | $28.43M | $14M | $2.06M | — | — | — | — | — | $31K | $440K | $586K | |
| $143.23M | $117.96M | $25.12M | $51.72M | $32.97M | -$31.65M | -$36.21M | -$10.44M | $9.6M | -$10.85M | -$35.93M | $8M | -$8.32M | -$5.74M | -$4.06M | -$2.68M | $13.9M | $95K | |
| — | $0 | -$7.01M | -$1.83M | $0 | $0 | — | $2.89M | $47.66M | $1.11M | -$23.13M | -$5.14M | $0 | $0 | — | — | — | — | |
| $45.48M | $18.43M | $75.02M | $46.37M | $28.54M | -$5.26M | -$16.93M | $1.05M | $50.38M | -$2.05M | — | — | — | — | — | — | — | — | |
| $237.96M | $158.96M | $2.52M | $63.66M | $36.01M | $72.21M | $1.29M | $796.64M | $173.33M | $57.23M | $7.96M | $35.33M | $11.3M | $9.21M | -$3.87M | -$3.56M | -$15.4M | -$9.87M | |
| $40.74M | $34.51M | $6.55M | $9.84M | $41.23M | -$4.15M | -$5.31M | $167.34M | $30.01M | $44.68M | $10.33M | -$192.12M | $410K | $374K | -$1.19M | -$13.27M | -$2.62M | -$1.54M | |
| $197.22M | $124.45M | -$4.03M | $52.15M | -$33.36M | $57.14M | -$2.99M | $629.3M | $143.32M | $12.56M | -$1.64M | $229.82M | $12.02M | $11.42M | -$527K | $9.72M | -$10.37M | -$1.95M | |
| — | 46.42% | -2.41% | 39.72% | -17% | 23.66% | -1.82% | 523.19% | 57% | 8.9% | -1.5% | 319.58% | 18.63% | 23.32% | -1.68% | 32.34% | -44.07% | -5% | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | $2.38M | -$1.13M | $0 | $0 | — | — | — | |
| $193.2M | $138.85M | -$9.16M | $52.32M | -$33.43M | $57.02M | -$3.57M | $630.11M | $142.47M | $12.3M | -$3.8M | $229.79M | $14.06M | $14.33M | -$527K | $9.68M | -$10.86M | — | |
| USD/shares | — | $6.44 | -$0.22 | $3.02 | -$1.98 | $3.44 | -$0.18 | $20.67 | $4.22 | $0.37 | -$0.05 | $7.24 | $0.37 | $0.35 | -$0.02 | $0.31 | — | — |
| USD/shares | — | $6.13 | -$0.22G | $2.94 | -$1.98 | $3.31 | -$0.18 | $19.87 | $3.72 | $0.33 | -$0.05 | $6.76 | $0.35 | $0.34 | -$0.02 | $0.31 | — | — |
| shares | — | 19.34M | 18.29M | 17.3M | 16.87M | 16.63M | 16.19M | 30.45M | 33.92M | 33.71M | 33.39M | 31.72M | 32.73M | 32.56M | 31.82M | 31.51M | 31.44M | 30.24M |
| shares | — | 20.29M | 18.29M | 17.76M | 16.87M | 17.25M | 16.83M | 31.67M | 38.58M | 37.64M | 33.39M | 34.03M | 34.36M | 33.25M | 31.82M | 31.6M | 31.44M | 30.24M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2010–FY2025: $743.37M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
19.42×
Peer median 7.46×
EV/EBIT
59.55×
Peer median 24.88×
P/E (TTM)
30.53×
Peer median 17.38×
Peer medians compare against the 185 similar-size Biotechnology companies (of 545 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Development and Licensing of Biopharmaceutical Assets | $268,087,000 | $167,133,000 | $131,314,000 | $196,245,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Royalty | $161,001,000 | $108,773,000 | $84,959,000 | $72,912,000 | — | $33,796,000 | $46,976,000 | $128,556,000 |
| Intangible Royalty Assets | $132,534,000 | $95,329,000 | $83,910,000 | $72,527,000 | — | — | — | — |
| Contract Revenue and Income | $66,873,000 | $27,477,000 | $17,983,000 | — | — | — | — | — |
| Contract Revenue | $66,873,000 | $27,477,000 | $17,983,000 | $18,838,000 | $28,367,000 | $19,807,000 | $41,817,000 | $93,774,000 |
| Income from Divestiture Transactions | $53,072,000 | $0 | $0 | — | — | — | — | — |
| Material Sales Captisol Core | $40,213,000 | $30,883,000 | $28,372,000 | $16,429,000 | $23,423,000 | $24,566,000 | — | — |
| Material Sales Captisol | $40,213,000 | $30,883,000 | $28,372,000 | $104,495,000 | — | $109,959,000 | $31,489,000 | $29,123,000 |
| Royalty Kyprolis | $35,534,000 | $38,377,000 | $35,640,000 | $30,116,000 | $27,472,000 | $25,164,000 | $25,046,000 | $21,686,000 |
| Filspari | $31,971,000 | $12,179,000 | $2,655,000 | $0 | — | — | — | — |
| Financial Royalty Assets | $28,467,000 | $13,444,000 | $1,049,000 | $385,000 | — | — | — | — |
| QARZIBA | $23,739,000 | $11,120,000 | $0 | — | — | — | — | — |
| Royalty Rylaze | $13,350,000 | $13,743,000 | $13,520,000 | $8,796,000 | — | $0 | — | — |
| Royalty Other | $10,366,000 | $7,486,000 | $6,760,000 | $6,550,000 | — | $2,255,000 | $2,566,000 | $1,952,000 |
| Capvaxive | $10,059,000 | $626,000 | $0 | — | — | — | — | — |
| Ohtuvayre | $9,760,000 | $833,000 | $0 | — | — | — | — | — |
| Royalty Teriparatide Injection | $8,148,000 | $8,221,000 | $11,061,000 | $15,785,000 | — | $0 | — | — |
| Vaxneuvance | $7,403,000 | $5,184,000 | $4,062,000 | $1,083,000 | — | — | — | — |
| License Fees | $6,988,000 | $1,944,000 | $0 | $0 | $634,000 | $119,000 | $6,199,000 | $78,195,000 |
| Service | $6,813,000 | $25,533,000 | $17,983,000 | $18,838,000 | $3,737,000 | $9,330,000 | $16,776,000 | $4,749,000 |
| Royalty Evomela | $5,943,000 | $8,680,000 | $10,212,000 | $10,197,000 | $10,079,000 | $6,377,000 | $5,171,000 | $5,658,000 |
| Financial Royalty Other | $4,728,000 | $2,324,000 | $1,049,000 | — | — | — | — | — |
| Contract Revenue and Other Income | — | $27,477,000 | $17,983,000 | $18,838,000 | — | — | — | — |
| License Fees Milestones And Other Product Other | — | — | $1,400,000 | $6,107,000 | $6,412,000 | $5,141,000 | $1,669,000 | $4,253,000 |
| License Fees Milestones and Product Other | — | — | — | — | — | — | $41,817,000 | $93,774,000 |
| Material Sales Captisol COVID | — | $0 | $0 | $88,066,000 | $140,827,000 | $85,393,000 | — | — |
| Milestone | — | — | $16,800,000 | $9,150,000 | — | $5,217,000 | $17,173,000 | $6,577,000 |
| Royalty Promacta | — | — | — | — | — | — | $14,193,000 | $99,260,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Development and Licensing of Biopharmaceutical Assets | $124,453,000 | -$4,032,000 | $53,819,000 | -$5,219,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Development and Licensing of Biopharmaceutical Assets | 46.4% | -2.4% | 41% | -2.7% |
Key facts
CIK
886163
CUSIP
53220K504
13F (30d)
381 filings
376 filers
Visit website
Investor relations